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Background: Inappropriateness of medicine use among older people is a growing concern as 
populations are aging. As a solution, collaborative medication reviews have been implemented 
into various health care systems and settings, also increasingly involving community 
pharmacists.  
 
Objectives: To identify 1) medication review interventions for older adults that involve 
community pharmacists and 2) evidence of outcomes of these interventions. 
   
Design: A systematic review was performed. Cinahl, MEDLINE (Ovid), Scopus, International 
Pharmaceutical Abstracts (IPA) and Cochrane Library were sought for articles published 
between January 2000 and February 2016. Articles involving community pharmacists in 
medication reviews for outpatients ≥65 years were included. Evidence on economic, clinical 
and humanistic outcomes of the interventions was summarized.  
 
Results: Sixteen (16) articles were found considering 12 different medication review 
interventions of which 6 were compliance and concordance reviews, 4 were clinical medication 
reviews and 2 were prescription reviews according to Clyne et al. typology. Community 
pharmacists’ contribution to reviewing medications varied from sending the dispensing history 
to other health care providers to a comprehensive involvement in patient’s medication therapy 
management. The most commonly assessed outcomes of the interventions were medication 
changes leading to a reduction in actual or potential drug-related problems (DRPs) (n=12) and 
improved adherence (n=5).  
 
Conclusion: Regardless of the community pharmacists’ contributions to interventions, 
medication review interventions seem to reduce drug-related problems and improve medication 
adherence.  More well-designed, rigorous studies with more sensitive and specific outcomes 
measures need to be conducted to assess the actual impact of the community pharmacists’ 




Collaborative medication review, Medication therapy management, Community pharmacist, 


















Inappropriateness of medicine use among older people is a growing concern worldwide as 
populations are aging. Older people are vulnerable to drug-related problems (DRPs) that can 
be potentially harmful, such as use of medicines without diagnosis, untreated diagnoses, poorly 
planned combinations of medications with clinically significant interactions, serotonergic and 
anticholinergic load, adverse drug reactions, inappropriate duration of medication therapy and 
poor adherence (1). Strategies to solve these problems or even prospectively prevent them to 
occur has actively been sought (2,3).  
 
As drug-related problems seem to be often linked to poor coordination of care of individual 
patients, leading to the situation that no one in the care team has overall responsibility of the 
entire medication or no one regularly reviews the medication, medication reviews have become 
an important intervention to assure appropriateness of medications of individual patients. 
Medication reviews, generally carried out by physicians, increasingly involve also pharmacists 
and nurses (4).  These collaborative interventions are frequently performed in various settings, 
such as hospitals, nursing homes and primary care, but evidence of their effectiveness is still 
scarce (5). Community pharmacists are also more and more involved in patient care and 
contribute to reviewing patients’ medications. They have potential for active involvement 
because they meet with older residents regularly while dispensing and may know their 
everyday health concerns. The aim of this systematic review was to identify 1) medication 
review interventions targeted at older adults (≥65 years) that involve community pharmacists 




Search Strategy  
 
A literature search was conducted in December 2014 and updated in February 2016 with the 
help of an information specialist on Cinahl, MEDLINE (Ovid), Scopus, International 
Pharmaceutical Abstracts (IPA) and Cochrane Library. Articles published within the period 
January 2000-February 2016 were included in the study. The search terms covered the 
following themes: interprofessional, collaboration and use of medicines / medication reviews.  
The Medical Subject Headings (MeSH) and other terms were used (see an example of the 
search strategy in Supplementary Dataset S1). This systematic review was carried out by 
following the Cochrane Collaboration guidelines where applicable (6). The PRISMA checklist 
was utilized throughout the study (7).  
 
Inclusion and Exclusion Criteria 
 
Original studies and systematic reviews on collaborative medication review interventions for 
older adults were included if they involved outpatients ≥65 years, community pharmacists 
contributed to medication reviews, and studies were carried out in developed countries (8). The 
medication review interventions with only consultant pharmacists were excluded because the 
interest was in community pharmacists’ involvement in medication reviews. No limits were set 
for research methods nor outcome measures. No control group was required. Articles written 




Study selection  
 
The search produced 4265 potentially relevant articles (Supplementary Figure S1). The search 
focused on all collaborative medication review interventions in different health care settings of 
which 16 dealt with community pharmacists’ contribution to medication review interventions 
(19-24). Two researchers (SK, AK) independently selected the studies based on titles and 
abstracts and reviewed the full texts of potential articles for final inclusion. All disagreements 
were resolved through discussion and consensus with the help of the third researcher (MPM) 
when necessary.  
 
Data extraction and analysis  
 
Data were extracted using extraction tables (Table 1; Table 2; Supplementary Tables S1-S3) 
that compiled the following information: medication review intervention and community 
pharmacists’ contribution to it, study design, method for outcome assessment, selected 
outcome measures applied and the study’s outcomes. For assessing the comprehensiveness of 
each medication review intervention, the Clyne et al. typology was used (25).  It classifies 
medication reviews into three categories according to the purpose of the review:  1) 
Prescription reviews address technical issues relating to the prescription that can improve the 
clinical use and cost-effectiveness of medicines and patient safety. It is based on reviewing the 
medication list and does not require the patient to be present. 2) The compliance and 
concordance review considers patient’s beliefs about medicines and practical barriers for 
medicine-taking. It usually requires the patient or patient’s carer to be present. 3) A clinical 
medication review is a comprehensive review that takes place with the patient and with access 
to the patient’s notes and laboratory values. It addresses issues relating to the patient’s use of 
medicines in the context of their clinical condition. The medication review process was 
considered to have the following steps modified from Hepler & Strand’s Pharmaceutical Care 
model (26): 1) Identification of the patients enrolled in the medication review intervention; 2) 
patient data collection; 3) interviewing the patient; 4) conducting the medication review; 5) 
counselling the patient; 6) contacting the GP about the medication changes; and 7) following 
up on the implementation of medication changes.  The community pharmacists’ reported 
contribution to each step in medication review interventions was categorized and analyzed. 
Evidence of economic, clinical and humanistic outcomes of the interventions were summarized 






Sixteen (16) articles met the inclusion criteria, all published in English. Five of the studies were 
randomized controlled trials (RCTs) (10,12,13,19,20), one of them being a multicenter study 
carried out in 7 European countries (10). The reminder of the articles (n=11) reported 
intervention studies (n=2) (9,24), document analyses (n=4) (17,18,21,22), qualitative 
interviews (n=2) (15,16), a process description (n=1) (11), and a cohort study (n=1) (23) 
(Supplementary Table S2). One study combined qualitative interviews and a survey (14). 
Studies were conducted in 13 countries, most commonly in Australia (n=3) (17,18,21), New 




Medication review interventions involving community pharmacists  
 
The articles (n=16) considered 12 different medication review interventions involving 
community pharmacists (Supplementary Table S1). Five of the interventions were discussed 
in more than one article (10,12,13-19) and one of the studies compared two different 
medication review interventions in two different articles (13,14). Most commonly the 
interventions were compliance and concordance reviews (n=6) (9-12,20,23,24), followed by 
clinical medication reviews (n=4) (15-19,21,22) and prescription reviews (n=2) (13,14). Table 
1 summarizes community pharmacists’ contributions to medication review interventions which 
are presented in more detail in the following paragraphs. 
 
Table 1. Community pharmacists’ contribution to seven steps of medication review 
interventions (n=12). Names of the interventions are given as in the articles. 
7 STEPS OF MEDICATION  
REVIEWS: 
Identificati- 















































































✓ ✓ ✓ ✓ ✓ ✓ ✓ 
(no specific 
name) (9) ✓ ✓ ✓ ✓ ✓ ✓ 
 








































Prescription reviews (two interventions, two articles) 
 
Both articles, which considered prescription reviews, were about the same intervention 
(treatment review) experimented in two variations in the Netherlands (13,14). Community 
pharmacists contributed to the identification of the patient with potential DRPs by a 
computerized tool integrated in the dispensing data system within the community pharmacy 
(13,14). They passed on information on clients with a DRP risk to other health care providers. 
The difference between the two variations of treatment review was the feedback that was given 
to GPs either in writing or in case-conferences. In those which had case-conferences between 
community pharmacists and GPs, the community pharmacists also contributed to follow-ups. 
 
Compliance and concordance reviews (six interventions, seven articles)  
 
Two of the articles considering compliance and concordance reviews were about the same 
multicentre study with the same intervention (10,12). In five out of the six interventions 
community pharmacists used their patient records to identify patients with potential DRPs 
and/or for collecting information on patients’ medication use (9-12,20,24). The community 
pharmacist interviewed the patient in five interventions (9-12,20,24). Following the medication 
review, the community pharmacist discussed the medication with the patient in all the six 
interventions (9-12,20,23,24). Community pharmacists also contacted patients’ GPs about 
DRPs when needed in all the interventions (9-12,20,23,24) and they contributed to follow up 
the patient in four interventions (10-12,20,24).  
 
Clinical medication reviews (four interventions, seven articles)  
 
Seven articles on clinical medication reviews concerned four different interventions (15-
19,21,22). Three of the articles related to government funded Home Medicines Reviews 
(HMR) (28) in Australia and reported studies on two approaches to HMR (17,18,21). In the 
other HMR intervention, community pharmacists interviewed the patients to obtain a 
comprehensive medication profile and, after conducting the review, wrote a report on the HMR 
findings and recommendations to the GP (17,18). In the other HMR intervention, community 
pharmacists contributed by sending the patients’ dispensing history to the pharmacists working 
in the medical center who reviewed the medications (21).  
 
Three articles considered the same General Practitioner–Pharmacist Collaboration (GPPC) 
experimental intervention in New Zealand (15,16,19). Community pharmacists contributed 
comprehensively to every step of the medication review intervention and had access to patients’ 
medical records and laboratory values. Community pharmacists also made recommendations 
for medication changes to the patients’ GPs and followed up with the patients clinically during 
the study period and updated the care plan when needed.   
 
In the Comprehensive Medication Review (CMR) in Finland identification of patients with 
potential DRPs was made by GPs (22). After receiving the necessary clinical information from 
the GP, the community pharmacist interviewed the patient at home, prepared a structured case 
report for the GP and discussed it jointly in a face-to-face case conference to decide on actions 





Outcome measures applied and effectiveness of the medication review interventions 
 
Main outcomes of the studies are summarized in Table 2. Outcome measures applied and 
findings on the effectiveness of the medication review interventions are detailed in 
Supplementary Tables S2 and S3.  In most of the studies (n=13), outcomes were measured as 
indirect clinical outcomes (9-14,17-20,22-24), the Beer’s criteria for potentially inappropriate 
medications (PIMs) (n=2) (18,23), Morisky’s Medication Adherence Scale (n=2) (23,24) and 
Medication Appropriateness Index (MAI) (n=2) (17,19) being used in more than one study. 
Quality of life was assessed in four of the studies, mostly by using SF-36 (n=3) (10,12,19) or 
EQ-5D-5L (n=1) (24). Economic outcomes were reported in seven articles (8,9,12-
15,22,23,26), direct costs (n=5) (9,10,12,13,24) and time spent on the intervention (n=4) 
(10,13,14,21) being the most commonly measured.   
 
Table 2. The outcome measures and the main outcomes of the studies (n=16) 




- Pharmacists’ recommendations and  
their acceptance (n=4) (10,13,19,20)  
- Medicine use and changes to medications 
(n=3) (10,12,19) 
- Sign and symptom control (n=2) (10,12) 
- Patient knowledge of medicines (n=2) 
(10,12) 
- Compliance with dosage regimens (n=2) 
(10,12) 
- Problems with medicines (n=1) (12) 
- MAI (n=1) (19) 
RCTs (n=5): 
Significant outcomes: 
- More medicines started in the control group (19) 
- More changes to medications in intervention group vs. control group (10, 19) 
- Intervention patients more compliant compared with the control patients (12) 
- MAI improved in the intervention group (19) 
Significance not reported: 
- 44% (17%-72%) of pharmacists’ recommendations accepted/partially accepted (10,13,19,20) 
- More changes to medications in case-conference group vs. written feedback group (13) 
- Better control of medications in intervention group (10,12) 
- Intervention patients more compliant compared with the control patients (10) 
- fewer problems with medicines in intervention group vs. control group (12) 
- 60,8 % (n=124) of the patients’ problems (n=204) identified led to positive outcomes (12) 
Other studies (n=11): 
Direct: 
- Falls (n=1) (24) 
- Pain (n=1) (24) 
 
Indirect: 
- Pharmacists’ recommendations and  
their acceptance (n=6) (11,14,17,18,22,24) 
- DRPs (n=4) (9,11,22,23) 
- Medicines use (n=2) (9,23) 
- Adherence (n=3) (9,23,24) 
- PIMs n=2 (18,23) 
- MAI (n=1) (17)  
- DBI (n=1) (18) 
Other studies (n=11): 
Significant outcomes: 
- Less falls (24) 
- More recommendations identified by the pharmacists themselves (than by computerized screening tool) in  
case-conference group (14) 
- DRPs (forgetfulness, DDIs, intermittent drug intake) decreased (23) 
- The median number of regular prescribed medicines fell from 6 to 5 (9) 
- Better adherence to medication (24) 
- Patients with non-adherence fell from 38 % to 14 % (9) 
- MAI scores lower after the intervention (17) 
- Reduction in the sum of total of DBI scores for all patients (18) 
Significance not reported: 
- 613 recommendations; 502 to patients (76 % accepted) and 247 to physicians (72 % accepted) (11) 
- 55% of pharmacists’ recommendations were accepted by physicians (22) 
- Pharmacists made 142 recommendations to prescribers in 110 patients (24)  
- 559 DRPs in 145 patients: 40 % of the DPRs were resolved, controlled or improved (11)  
- 785 potential DRPs (6.5/patient); 51% (n=403), resulted in change of drug therapy (22) 
- The number of patients with one or more DRPs reduced from 94 % to 58 % (9) 
- Intervention led to a decrease in the use of PIMs (18,23) 
- Better compliance (23) 
Non-significant outcomes: 
- Pain scores increased (24) 
- More recommendations to the GPs in case-conference group than in written feedback group (14) 
- Self-reported ADRs decreased (23) 
Humanistic outcomes 
RCTs (n=5): 
- HRQoL (SF-36) (n=3) (10,12,19) 
- Satisfaction/perceptions (n=2) (10,12) 
RCTs (n=5): 
Significant outcomes: 
- HRQoL: emotional role and social functioning reduced (19) 
- HRQoL: physical functioning and vitality improved in control group (12) 
- Intervention group more satisfied with the services than the control group (10) 
Significance not reported: 
- All patients rated services excellent or good (12) 
- Pharmacists and GPs had a positive opinion of pharmaceutical care (10,12) 
- HRQoL declined in intervention group (12) 
Non-significant outcomes: 
- HRQoL declined in general, non-significant differences between the control and intervention groups (10) 
Other studies n=11: 
- Perceptions/opinions (n=3) (14-16) 
- Ways to improve treatment review method 
(14) 
- HRQoL (EQ-5D-5L) (24) 
Other studies (n=11): 
Significant outcomes: 
-HRQoL improved (24) 
Significance not reported: 
- Pharmacists concerned that they lacked skills and confidence, not mandated to take this role (15) 
- GPs attributed different values to patient outcomes vs. use of resources which led to continuum between 
positive and negative responses (16) 
-Health care professionals were more positive about the process of the treatment review presented personally (14) 
Economic outcomes 
RCTs (n=5): 
- Cost of medication (n=3) (10,12,13) 
- Cost of intervention (n=2) (10, 13) 
- Time (n=2) (10, 13) 
- Number of patients’ contacts with health 
care professionals (n=2) (10, 12) 
- Hospitalization (n=2) (10, 12) 
RCTs (n=5): 
Significant outcomes: 
- Pharmacists in case-conference vs. written feedback group spent more time on the intervention (13) 
Non-significant outcomes: 
- Non-significant differences in total cost for intervention and control groups (10, 12, 13) 
- Lower costs of prescribed medicines in intervention compared to control (12) 
- Fewer intervention patients were hospitalized (12) 
Other studies (n=11): 
- Time (n=2) (14,21) 
- Cost of medication (n=1) (9) 
- Cost of intervention (n=1) (24) 
- Cost per QALY (n=1) (24) 
- The billing of the process made by the GPs 
as a marker of completion of Home 
Medicines Review process (n=1) (21) 
Other studies (n=11): 
Significant outcomes: 
- The time to complete the process reduced from median of 56 days to 20 (21) 
- The average cost of medication for 28 days fell from £51,12 to £44,55 (9) 
Significance not reported: 
- Pharmacists spent more time on the intervention than GPs did (14) 
- The case conference group required more time than the written feedback group (14) 
- The support programme resulted in projected savings of £52 per patient per year (9) 
- Cost of the intervention was estimated to be £98.72 per participant and the probability of being cost-effective 
was 13,8% (24) 
- Cost per quality-adjusted life year estimates ranged from £11 885 to £32 466 depending on the assumptions 
made (24) 
- A potential financial saving of AUS$ 17 374 during the post-integration phase (21)  
ADR = Adverse drug reaction, DBI = Drug Burden Index, DDI = Drug-drug interaction, DPR = Drug-related problem, GP = General practitioner, HRQoL = Health-related quality of life, 
MAI = Medication Appropriateness Index, PIM = Potentially inappropriate medication, QALY = Quality Adjusted Life Year, RCT = Randomized controlled trial
Randomized controlled trials (n=5)  
 
Five of the included studies were randomized controlled trials with the follow-up period ranging from 
9 to 24 months (10,12,13,19,20). None of the RCTs reported direct clinical outcomes. Indirect clinical 
outcomes considered the most commonly changes in medications (n=4) (10,13,19,20) and 
pharmacists’ recommendations to GPs (n=4) (10,13,19,20). Regardless of the comprehensiveness of 
the MRI or the community pharmacists’ contribution to it, more changes were implemented to 
intervention group patients than to controls. When reported, GPs accepted or partially accepted on 
average 44% of the pharmacists’ recommendations (17%-72%) (10,13,19,20). The proportion of 
actual medication changes was reported in four studies (10,13,19,20). Better compliance and control 
of medical conditions in the intervention group (n=2/2) (10,12) and significant improvement in MAI 
in the intervention patients (n=1/1) (19) was reported. 
 
Three RCTs (n=3) reported humanistic outcomes (10,12,19). The quality of life had been assessed by 
using the SF-36 and it mainly showed a decline in some quality of life dimensions, while only one 
study reported some improvement (12). Two studies (n=2) measured the opinions of the 
pharmaceutical care services and both reported mostly positive opinions from all parties involved 
(i.e., patients, GPs and pharmacists) (10,12). 
 
Economic outcomes were reported in two RCTs (10,12). Bernsten et al. (2001) reported some 
significant cost savings in some countries (10).  Sturgess et al. (2003) reported total costs per patient 
to be lower in the intervention group (12).  
 
Other studies (n=11) 
 
Eleven of the studies were other than RCTs and considered intervention studies (n=2) (9,24), 
document analyses (n=4) (17,18,21,22), qualitative interviews (n=2) (15,16), a process description 
(n=1) (11), a cohort study (n=1) (23) and combination of qualitative interviews and a survey (14). 
Regardless of the community pharmacists’ contribution to medication review interventions or their 
comprehensiveness, interventions led to a reduction in actual or potential DRPs (n=6/6) 
(9,11,17,18,22,23), better adherence (n=3/3) (9,23,24) and reduction in the number of medicines in 
use (n=2/2) (9,23). The only direct clinical outcome measured was the number of falls which was 
found to be fewer in the study group 6 months after the start of the intervention when the study 
participants performed as their own controls (24).  
 
Indirect clinical outcomes mostly considered community pharmacists’ recommendations to GPs to 
solve potential DRPs (n=6) (11,14,17,18,22,24). One of these studies compared two different 
prescription review interventions and reported that community pharmacists with a case-conference 
with the GP made significantly more recommendations which were better accepted than written 
recommendations (14).   
 
All the qualitative interview studies (n=3) reported humanistic outcomes described as health care 
providers’ perceptions on interventions (14-16). Both positive and negative perceptions were reported 
(14,15). 
 
Four studies assessed economic outcomes measured with different approaches (n=4) (9,14,21,24). 
Regardless of the community pharmacists’ contribution to intervention, three of the studies (n=3) 





This systematic review is the first one to summarize the evidence of the community pharmacists’ 
contribution to medication review interventions for older adults. The interventions varied in their 
comprehensiveness from prescription reviews to clinical medication reviews. Also the community 
pharmacists’ contribution to interventions varied from sending the dispensing history to other health 
care providers to accessing patients’ medical history, interviewing the patient, conducting the 
medication review, consulting/case-conferencing the findings with the GP, discussing the findings 
with the patient and following-up the implementation of the medication changes. Regardless of the 
community pharmacists’ contribution to medication review intervention, some positive outcomes 
were reported, mainly reduction in DRPs and improved adherence. Direct clinical evidence and 
evidence of economic outcomes of these interventions was scarce.  
 
The community pharmacists’ contribution was most extensive in compliance and concordance 
reviews. Particularly in compliance and concordance reviews community pharmacists involved 
patients by interviewing them to identify DRPs and advising them in medicine taking.  These findings 
and contributions indicate that community pharmacists can take more responsibility for patient care 
than they currently do. Their involvement could be facilitated by improving patient information 
transfer between community pharmacists and other health care providers, e.g., through electronic 
health records, if the access was extended to community pharmacists. In many of the reported 
interventions community pharmacists identified patients with potential DRPs by using medication 
records and computerized screening tools available in the pharmacy and transferred their findings to 
other health care providers. If the patient information transfer and communication were more 
accessible, community pharmacists’ ability to identify DRPs could be utilized more. The importance 
of information transfer, as a facilitator to interprofessional collaboration in medication optimization 
for the older adults, has been reported also in previous studies (5). 
 
Medication changes leading to a reduction of actual or potential DRPs and improved adherence were 
the measures that most commonly yielded significant outcomes for medication review interventions. 
Considerable attention had been paid to pharmacists’ recommendations and their acceptance by GPs, 
as well as on the changes in the number of medicines that patients used. All these are indirect 
outcomes and unspecific indicators of the quality of medication therapy. The number of medicines in 
use does not necessarily tell how rational the medication regimen is if there is no measurement taken 
e.g., for potentially harmful medicines and combinations of medicines, nor untreated conditions 
(29,30). The quality of life was measured only in few studies and showed conflicting results. This 
may reflect that the measures used were not specific and sensitive enough to indicate any change in 
the quality of life of older people with impaired coping skills in everyday life. Hence, for future 
studies, more sensitive and more specific quality of life measures, that have been validated for older 
people, should be developed (30).   
 
The extent of the community pharmacist’s contributions to medication review interventions, as well 
as assessment methods and outcomes measures applied, varied between studies. Therefore, it is 
difficult to estimate how the community pharmacists` contribution influenced the outcomes of the 
medication reviews. When reported, follow-up periods ranged from two months to two years which 
made it difficult to compare the studies. Interventions were heterogeneous and not always well-
documented in the studies which made it unclear what kind of medication review interventions were 
actually conducted. This may be due to the fact that most of the studies were primarily targeted at 
some other objectives than introducing a medication review intervention.  Given that the majority of 
the studies were descriptive and measured indirect clinical outcomes, more well-designed studies 
with validated and standardized outcome measures are needed to create more rigorous evidence (30). 
This may facilitate the development of more effective medication review interventions. 
 
The search strategy of this systematic review was comprehensive and the search covered the major 
potential scientific databases.  In addition, the reference lists of the included articles were reviewed 
to ensure that all relevant articles were identified. To avoid selection bias two or three researchers 
were involved in the selection process. Categorization of medication review interventions and 
community pharmacists’ contributions to the interventions were quite often challenging because the 
articles did not provide detailed and comprehensive information on the medication review 
interventions applied.  The comprehensiveness of the search strategy is also a limitation to the study. 
The aim of the original search was to find interprofessional medication review interventions without 
limiting it to community pharmacies. Therefore, the search terms were more general than specific 
which may have excluded some relevant articles.   
 
This systematic review indicates that community pharmacists could be more involved in health care 
teams and medication review interventions for older adults. There are some promising models in 
some countries, particularly in Australia, New Zealand and the Netherlands. The more extensive 
integration and implementation of these community pharmacy services requires recognition in 




Community pharmacists could be more involved in medication review interventions for older adults, 
their contribution extending from identification of DRPs towards more a holistic contribution to 
medication therapy management. Regardless of the community pharmacists’ contributions to 
interventions, medication review interventions seem to reduce drug-related problems and improve 
medication adherence.  More well-designed, rigorous studies with more sensitive and specific 
outcome measures need to be conducted to assess the actual impact of the community pharmacists’ 
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Supplementary Dataset S1  
Search strategy for the Medline 
 
1. medication therapy management.mp. or exp Medication Therapy Management/  
2. (medicat* adj3 managem*).mp.  
3. "medication therapy review".mp.  
4. medication reconciliation.mp. or exp Medication Reconciliation/  
5. (comprehensive adj3 medicat*).mp.  
6. (medicat* adj3 assessment).mp.  
7. (medicat* adj3 review).mp.  
8. (drug* adj3 review).mp.  
9. "clinical pharmacy service".mp.  
10. (prescription adj3 review).mp. 
11. "clinical interviewing".mp.  
12. "medication counseling".mp.  
13. (medicat* adj3 harm).mp.  
14. (drug* adj3 problem*).mp.  
15. polypharmacy.mp. or exp Polypharmacy/  
16. (adherence adj3 review).mp.  
17. "medication use process".mp.  
18. (medicat* adj3 appropriatene*).mp.  
19. (medicat* adj3 safet*).mp.  
20. inappropriate prescribing.mp. or exp Inappropriate Prescribing/ 
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 
18 or 19 or 20 22. interprofessional relation.mp. or exp Interprofessional Relations/  
23. inter?professional.mp.  
24. multi?professional.mp.  
25. multiprofessional.mp.  
26. interdisciplinary communication.mp. or exp Interdisciplinary Communication/  
27. interdisciplinary health team.mp. or exp Patient Care Team/  
28. "medical* care team".mp.  
29. team.mp. 62  
30. cooperative behavior.mp. or exp Cooperative Behavior/  
31. co?operative.mp.  
32. cooperative.mp.  
33. networking.mp.  
34. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33  
35. 21 and 34  
36. 34 and (comprehensive adj3 intervention).mp.  
37. 35 or 36  








































      
Literature Search in December 2014: 
 Cinahl (n=582)  Cochrane Library: Cochrane reviews (n=10) 
 Medline Ovid (n=1358)   Other reviews (n=2) 
 Scopus (n=1626)   Trials (n=188) 
 IPA (n=58)    Methods Studies (n=7) 
     Technology Assessments (n=1) 
     Economic Evaluations (n=5) 




Excluded duplications with Refworks (n=326) 
3511 titles screened 
Excluded according to the title (n=2485) 
Excluded remained duplications manually (n=456) 
570 abstracts screened 
Excluded according to the abstract (n=256) 
 Inpatient setting abstracts (n=120) 
194 full texts screened considering outpatient setting 
Excluded according to the full text (n=153) 
36 original articles and 5 systematic reviews included 
30 original articles and 1 systematic review added from the reference lists 
2 original articles and 1 systematic review identified by the research team 
68 original articles and 7 systematic reviews included 
Articles not considering community pharmacy (n=60) 
15 original articles considering community pharmacies in outpatient setting 
Update of the literature search in February 2016: 428 titles 
1 new original article considering community pharmacies in outpatient setting  
16 articles were included in the study 
Supplementary Table S1.  
Description of the medication review interventions (n=12) in included articles (n=16) and community pharmacists’ contribution to the interventions. 
Reference 
and country  
 
Study design 




given in the 
article 
Description of the medication 
review intervention 
Community pharmacists’ contribution to the medication review intervention 
Identificati- 






















I Prescription reviews (2 interventions) 
Denneboom 








1)  Patients (≥75 years, ≥5 
medicines) were selected from 
the community pharmacies 
database.  
 
2) The pharmacist received a 
list of potential problems 
identified by the computerized 
screening tool 
 
3a) The pharmacist listed all 
recommendations and delivered 
the written feedback to the GP 




3b) The pharmacist and the GP 
discussed all recommendations 
with each other and filled in a 
standardized pharmaceutical 
care plan. The follow-up by the 










From the  
database on  
pharmacies. 
- Deciding  




by the  
screening  
tool should  
be given to  







therapy of  
the patients  
should be  
highlighted. 
- a) Written  
feedback 
- 
b) A case- 
conference 
In 3 months  














II Compliance and concordance reviews (6 interventions) 
















assessed and identified patients 
individually with actual and 






1) educating the patient about 
their drug regimen and medical 
condition 
 
2) implementing compliance- 
improving strategies (e.g. drug 
reminder charts) 
 
3) rationalizing and simplifying 
drug regimens in collaboration 







from the GP 




By using  
number of  
data sources:  
the patient  
by a  
structured  
approach,  
the GP, the  
records  
within the  
pharmacy 
During the  
assessment. 
Identifying  
actual and  
potential  
DRPs using  






plan for the  
patient. 
Educating  
the patient  
about their  
drug  









zing drug  
regimens  
together  
with the GP 
6 monthly 








1) Identification of patients 
(community dwelling, ≥4 
prescribed medicines, regular 
visits to pharmacy) via 
computerized patient 
medication records kept within 
the pharmacy. 
 
 2) The pharmacist collected 
data to identify actual and 
potential DRPs. 
 
3) During the assessment, the 
pharmacist formulated an 
intervention and monitoring 
plan for the patients and visited 








From the  
patient via  
questioning,  
the patient’s  




as part of the  
assessment. 
Identifying  
actual and  
potential  
DRPs using  












plan for the  
patients and  
visiting them  
at home to  
assess  







referred to  
their GP or  
the GPs  
were  
contacted  
personally to  
discuss the  
problem. 
6 monthly  
(by e.g.  
pharmacist  
assistant) 
of medicines where problems 
were identified. 










Medication consultation: the 
community-based pharmacy 
resident reviewed the patient’s 
medication with the special 
attention on medications 
reported to increase the risk for 
falls. Resident faxed a note in 
the SOAP (Subjective 
information, objective 
information, assessment, and 
plan) to the prescribing 
provider. The prescriber 
informed the resident of the 
medication changes and the 







From the  
prescription  
records and  








DRPs and a  
risk for falls  





Faxing the  
note in the  
standard  
SOAP  




the patient  
by telephone  
and assisting  
with the  
implemen- 






















1) The GP decided which 
patients needed home visits. 
Inclusion criteria was any intake 
of medicines. 
 
2) Nurses interviewed patients 
at their home and had a home 
medication review. Standard 
interview detected adherence 
problems, ADRs during the last 
four weeks, the use of 
adherence supporting activities 
and record of all medicines 
(prescribed and over-the- 
counter) 
 
3) Pharmaceutical care by 
community pharmacist: the 
pharmacist received the report 
of patient’s medication and 
analyzed it. 
 
4) The pharmacist provided 
- - - Conducting 
pharma- 
ceutical care  
based on a  
standardi- 
zed report  






advice to the  
patient about  
correct drug  
usage. 
If necessary,  
recommenda 
tions to the  
GP for  
modificati- 




advice to the patient about the 
correct medicine usage and 
gave recommendations to the 
GP if necessary. 
 
5) A follow-up visit (not 
reported by whom) 












The community pharmacist 
telephone interviewed the 
patients (≥65 years of age, ≥3 
medicines according to 
pharmacy dispensing records). 
The pharmacist used PMDRP 
(Pharmacists’ Management of 
Drug-Related Problems) form 
and SOAP (Subjective 
information, objective 
information, assessment, and 
plan) notes to document care. 
The pharmacist made 




Using the  
PMDRP  






on of DRPs  
based on the  
PMDRP  
form and  
they were  
ranked  
according to  
importance.  
Interventi- 
ons were  
documented  
using SOAP  
notes. 
Recommen- 
dations and  
counselling  
for the  
patients 
Recommen- 
dations for  
patients’ GP 
Follow-up  
plan written  
in the SOAP  
notes,  
Following  




Raynor et al. 






1) Local general practice 
surgery computer identified 
patients ≥65 years  
 
2) The pharmacy patient 
medication records system 
identified patients with ≥4 
regular medicines. 
 
3) Pharmacy and surgery staff 
identified the patients living 
alone by their personal 
knowledge. 
 
4) The pharmacist conducted 
structured assessment interview 
at the patients’ home: the 
reviewing of patients’ 
medicines, issues relating to 





















From the  
patient. 
At the  
patient’s  
home using  











following a  
discussion  
with the  
patient and  
writing an  
action plan.  
Implemen- 
tation of  
necessary  
changes to  
the patient’s  
medication 
The second  
home visit:  
discussion  
with the  
patient of  
medication  




Liasing with  
the GP about  
implementati 
on of  
medication  





5) The pharmacist drew up an 
action plan. Liasing with the GP 
and other carers. 
 
6) The pharmacist made a 
second home visit with a new 
supply of medicines, discussed 
the medication regimen with the 
patient and explained any 






Twigg et al. 










1) Pharmacy or another health 
care professional (e.g. GP) 
invited the patient to the 
service.  
 
2) Pharmacist used patient 
medication records and a subset 
of STOPP/START criteria. 
These criteria were listed on the 
patient’s personal service 
record. If particular criterion 
was present, then the 
pharmacist ticked the box, and 
this prompted them to make a 
recommendation to the GP 
 
3) Pharmacist discussed the 
assessment with the patient and 
asked specific questions relating 
to fall risk, pain management 
and adherence, where 
appropriate. The pharmacist 
made recommendations to the 
patient and referred to the GP 
when necessary. 
 
4) The pharmacist discussed the 
STOPP/START assessment 









nals who had  
told patients  
about the  
service. 







with the  







record and a  






tions to the  




tions to the  
GP if  
necessary. 
On a regular  
basis  
depending  





or feel a  
need. 
 
5) Patients met with the 
pharmacist on a regular basis 
depending on when they 
collected their medications or 
they felt a need. 
III Clinical medication review (4 interventions) 











1) GPs invited the patients.  
 
2) Gathering of patient 
information (pharmacist had 
access to patients’ medical 
records information including 
problem list, medication and 
laboratory values) 
 
2) Medication review in 
pharmacy or at patient’s home. 
The use of standardized 
comprehensive data-collection 
forms. Recommendations to the 
prescriber and patient. 
 
3) Follow-up consultation with 
the patient. 















In pharmacy  








of drug  
therapy  
problems.  
Preparing a  
care plan. 
Consultati- 
on with the  
patient. 
Recommen- 
dations to  
the GP in a  
meeting  






on with the  
patient at 3,  
6 and 12  
months and  
updating the  
pharma- 
ceutical care  
plan when  
needed. 











Pharmacist met with the patient 
(>65 years of age, ≥5 
medicines) with access to 
patient medical records, and 
then met the GP to discuss 
potential medication alterations. 
- see above see above see above see above see above see above 











Pharmacist met with the patient 
(>65 years of age, ≥5 
medicines) with access to 
patient medical records, and 
then met the GP to discuss 
potential medication alterations. 
The patient was met in 
pharmacy or at home. A 
meeting with the GP. 
- see above see above see above see above see above see above 
Castelino et 










1) The GP referred the patient 
to the patient’s preferred 
pharmacy based on standard 
criteria (≥5 medicines or a 
medicine with narrow 
therapeutic index). 
 
2) Pharmacist interviewed the 
patient usually in the patient’s 




3) the pharmacist wrote a report 
on HMR findings and 
recommendations to the GP. 
 
4) The GP and the patient 
agreed on a medication 
management plan based on the 
HMR report. 
- From the  
patient’s  
interview 
Usually in  
the patient’s  
home 
After the  
interview  
pharmacist  



















(see above) - see above see above see above - see above - 




In the medical center, the GP or 
the community nurse identified 
- Community  
pharmacies  












the patient for a HMR. The GP 
signed the referral and gave it to 
practice pharmacist who sent a 
copy to patients’ community  
pharmacy. The community 
pharmacy sent copy of the 
patients’ dispensing history and 
any other relevant information. 
The practice pharmacist 
interviewed the patient in the 
medical center or at the 
patient’s home to identify 
DRPs. The HMR report was 
uploaded into the medical 
software with an alert sent to 
the GP and the copy was sent to 
the community pharmacy. The 
practice pharmacist discussed 
the medication review with the 
GP. The patient was called for 
an appointment with the GP and 
may be referred for another 
HMR later if the GP considers 
it necessary 
received a  
copy of the  
HMR  
referral from  
practice  
pharmacist  
and sent  
back a copy  
















1) The GP selected the patients 
based on potential problems or 
risks in the patients’ 
pharmacotherapy. 
 
2) The patients were asked for a 
written consent. 
 
3) The GP provided patients’ 
clinical information to the 
community pharmacist. 
 
4) The pharmacist interviewed 
the patients at patients’ homes 
using a structured interview 
form. 
 
- From the  
patient’s GP 
At the  
patient’s  
home using  




DRPs based  
on clinical  
information  
and the  
interview.  
Preparing a  
structured  
case report. 
- A structured  
case report  
with  
findings and  
recommen- 
dations to  




to determine  
actions.  
Documenta- 
tion of  
decisions to  
the case  
report. 
- 
5) The pharmacist prepared 
structured case reports for each 
patient with findings and 
recommendations for the GP. 
 
6) The pharmacist and the GP 
(and a nurse) had a face-to-face 
case conference to determine 
actions. The decisions were 
documented on the case report. 
DRP = Drug-related problem 
GP = General practitioner 
RCT = Randomized controlled trial 
STOPP = Screening Tool of Older Person’s Prescriptions 
























Supplementary Table S2. Description of studies (n=16). 
Reference Aim of the study Patients Control Time Outcome measures 
Bernsten et  










Republic of  
Ireland and  
Sweden 
To measure the outcomes of a  
harmonized, structured  
pharmaceutical care  
programme provided to  
patients (≥65 years of age, ≥4  
prescribed medicines) by  
community pharmacist in a  
multicentre international  
study performed in 7  
European countries 
Community dwelling,  
≥65 years of age, ≥4  
prescribed medicines.  
Patients were required  
to orientate with  
respect to self, time  
and place. Regular  
visits to community  
pharmacy. n = 1290  
from 104 pharmacies  
received structured  
pharmaceutical care  
programme. 
Community dwelling,  
≥65 years of age, ≥4  
medicines. Regular  
visits to community  
pharmacy. n = 1164  
from 86 pharmacies  
received normal  
services. 
18 months  
(0,6,12, and 18) 
Clinical:  
Indirect:  
-sign and symptom control 
-Medicines use 
-Number of times medication regimens were changed  
-GPs’ acceptance of recommendations  
-Patient knowledge of medicines 
-Compliance with dosage regimens 
(questionnaires developed by the research group) 
Humanistic:  
-HRQoL (SF-36) 
-Patient satisfaction with the services (a  
questionnaire) 
-The pharmacists’ and GPs’ satisfaction  
(a questionnaire) 
Economic: 
The total cost of intervention divided into:  
- additional time spent by pharmacists 
- patients contacts with GPs, specialists and nurses 
- number of hospital admissions 
(self-reported by the pharmacists and the patients) 
- cost of drugs prescribed 
(from pharmacy records) 
Bryant et al.  
2011 (19)  
RCT  
 
To determine whether the  
involvement of community  
pharmacists undertaking  
medication reviews, working  
≥65 years of age, ≥5  
prescribed medicines  
received  
Comprehensive  
65 years of age, ≥5  
prescribed medicines  
received usual care  
n = 229 
12 months:  
Intervention  
group: 0,3, 6  




- change in the numbers of medicines used 
New  
Zealand 
with GPs, improved  
medicine-related therapeutic  
outcomes for patients. 
Pharmaceutical Care  
(CPC)  
n = 269  
The control  
group received  
the intervention  
at 6 months and  
were followed at  
0,3, and 6  
months.  
- the number of changes to medicines therapy  
- number of recommendations made and  
implemented  
Humanistic: 
- QoL (SF-36) 
Economic:- 
Casteel et al.  




To report on retrospective  
process evaluation of data  
from a RCT conducted to  
examine the effectiveness of a  
medication review  
intervention, delivered  
through community  
pharmacies, on the rate of  
falls among community- 
dwelling older adults.  
≥65 years of age, ≥4  
prescription medicines  
filled in the previous  
12 weeks and had  
prescription filled for  
≥1 high-risk  
medication.  
+ having fallen in the  
last 12 months, living  
at home, able to come  
to a pharmacy,  
knowing English  
language, <3 errors on  
the Mini-Mental State  
Examination. 
Received medication  
consultation. 
n=93 
≥65 years of age, ≥4  
medicines filled in the  
previous 12 weeks and  
had prescription filled  
for ≥1 high-risk  
medication.  
+ having fallen in the  
last 12 months, living at  
home, able to come to a  
pharmacy, knowing  
English language, <3  
errors on the Mini- 
Mental State  
Examination. 
n=93 
24 months:  
prescriptions  
filled 12 before  
randomizations  
continuing 12  




- whether the prescriber authorized the  
recommendations made by the pharmacy resident  
- whether the recommendations were implemented or  
not implemented  
- the number of recommendations made by pharmacy  
residents 




et al. 2007  
(13)  




To compare two different  
procedures for treatment  
reviews (case conferences and  
written feedback) and the  
number of medication  
changes in them. To  
determine the costs and  
savings related to the  
intervention. 
home-dwelling ≥75  
years of age, ≥5  
prescription medicines  
continuously. 
Two intervention  
groups: 
1) a written-feedback  
group: 
351 patients in 13  
pharmacies 
2) a case-conference  
group: 387 patients in  
15 pharmacies 
The two intervention  
groups were each  
other’s controls 
9 months: 
(0,6 and 9) 
Clinical:  
Indirect: 
- the number of clinically-relevant recommendations  
(clinical relevance identified by earlier analysis,  
literature or an expert panel) 
- the number of medication changes following the  
recommendations  
- whether the medication changes had been  
maintained  
- clinical relevance of the recommendations leading  
to medication changes 
Humanistic:- 
Economic:  
- Changes in costs of medicines used 
- Costs of the treatment reviews  
- Time consumed by the intervention  
Sturgess et  





To measure the outcomes of a  
harmonized, structured  
pharmaceutical care  
programme provided to  
elderly patients by  
community pharmacists. 
Elderly, ambulatory,  
community dwelling  
patients 65 years of  
age, ≥4 prescribed  
medicines, regular  
visits to community  
pharmacy received  
pharmaceutical care  
intervention.  
Patients were required  
to orientate with  
respect to self, time  
and place.  
(n=110) 
Elderly, ambulatory,  
community dwelling  
patients 65 years of age,  
≥4 prescribed  
medicines, regular visits  
to community pharmacy  
received normal  
services. Patients were  
required to orientate  
with respect to self, time  
and place.  
(n=81) 
18 months  




- Medicines use 
- Number of changes in medicines 
- Problems with medicines  
- Sign and symptom control 
- Patient knowledge of medicines 
- Compliance with dosage regimens 
(questionnaires developed by the research group) 
Humanistic:  
- HRQoL (SF-36) 
- Patient satisfaction with the services provided 
(a questionnaire) 
- Pharmacists’ perceptions of the study and  
pharmaceutical care (a questionnaire) 
Economic:  
- Costs 
- Number of hospitalisations 
- Medicines use 
- Number of patients’ contacts with health care  
professionals 
Bryant et al.  





To explore possible  
attitudinal factors that prevent  
increased participation of  
community pharmacists in  
medication reviews  
undertaken in collaboration  
with GPs. 
Pharmacists who had 





- Interviews were  
undertaken at  




- Community pharmacists’ perceptions of clinical  
medication reviews 
Economic:- 
Bryant et al.  





To explore the perceptions of  
GPs to determine possible  
barriers that limit community  
pharmacists and GPs working  
together clinically. 






- Interviews were  
undertaken at  




- GPs’ perceptions of clinical medication reviews  
undertaken by community pharmacists. 
Economic:- 
Castelino et  







To retrospectively evaluate  
the impact of Home  
Medicines Reviews (HMRs)  
on the appropriateness of  
prescribing. 
Community-dwelling 
older people (≥65 
years, on the basis of 
standard criteria, e.g. 
≥5 medicines or 
medicine with narrow 
therapeutic index) 
(n=270) 
- Retrospectively  
from HMRs  
conducted  
between  
February 2006  




- MAI scores at baseline and after the HMR service  
as a tool to categorize pharmacists’ recommendations 
Humanistic:- 
Economic:- 
Castelino et  







To investigate whether Home  
Medicines Review (HMR)  
services would lead to an  
improvement in the use of  
medicines. 
Community-dwelling 
older people (≥65 
years, on the basis of 
standard criteria, e.g.  
≥5 medicines or 
medicine with narrow 
therapeutic index) 
(n=372) 
 Retrospectively  
from HMRs  





- The total Drug Burden Index (DBI) score at  
baseline and post-HMR 
- The extent of PIM use (2003 Beers’ criteria) 












To describe the feasibility of  
two methods for treatment  
review (case conferences and  
written feedback) 
Patients ≥75 years of 
age, ≥5 medicines. 
Two intervention 
groups: 
1) a written-feedback 
group: 
- 351 patients 
- 13 pharmacists of 
whom 9 randomly 
selected were 
telephone interviewed 
- 8 randomly selected 
- Written  
questionnaires  
were sent after  
treatment  
reviews.  
Reminders of  
questionnaires  
after 2 and 5  
months. 
 
Interviews were  
conducted after  
Clinical:  
Indirect: 
- the number of recommendations for each patient 
- the number of clinically relevant recommendations 
(clinical relevance identified by earlier analysis,  
literature or an expert panel) 
- origin of the recommendations  
(pharmacist/computerized screening tool) 
Humanistic: 
- GPs and pharmacists’ opinions of the treatment  
review 
- ways to improve treatment review method 
GPs were telephone 
interviewed 
2) a case-conference 
group:  
- 387 patients  
- 15 pharmacists 
of whom 9 randomly 
selected were 
telephone interviewed  
- 8 randomly selected 





- time spent in performing treatment reviews 
Fiß et al.  










To reduce several DRPs by  
the implementation of a three  
party health care team and  
adherence supporting  
strategies 
Home-dwelling 
elderly in German 
rural areas (n=408) 





time 9 months. 
Clinical:  
Indirect 
- self-reported DRPs  
(Morisky Scale; study specific questions) 
- objectively evaluated DRPs  
(PI-Doc system; ABDA Database)  
- PIMs (Beer’s criteria)  
- Medicines use  
(active substances identified by using ATC-codes)  
- prevalence of adherence supporting strategies  
(study specific questions) 
Humanistic:- 
Economic:  
Freeman et  




analysis of  
medication  
reviews with  




To describe the effect of  
integrating a pharmacist into  
the GP team on the timeliness  
and completion of  
pharmacist-conducted  
medication reviews compared  
with referral for Home  
Medicines Review (HMR) to  
a community pharmacist 
Patients who had 
received referral for 






integration of practice 
pharmacist (n=314). 
- Two time  
periods were  
analysed: Pre- 
integration of  
practice  
pharmacist from  
October 2001 to  
March 2009 (90  
months) and  
post-integration  
of practice  




- the billing of the process made by the GPs as a  
marker of completion of HMR process 
- the median number of days between HMR referral  
and the pharmacist consultation with the patient with  
the median number of days between HMR referral  
April 2009 to  
May 2010 (12  
months). 
and the GP follow-up consultation with the patient  
(the entire medication review process) 
- the proportion of patients seen by the pharmacist  
and the GP at follow-up at 2 and 4 weeks 
Kassam et  
al. 2001 (11) 
 
Descriptive  
analysis of  
the treatment  








To describe the process of  
care used by community  
pharmacists participating in  
the Pharmaceutical Care  
Research and Education  
Project (PREP). 
Patients ≥65 years of 
age, ≥3 concurrently 
used medicines 





- 15 months Clinical:  
Indirect: 
- frequency of DRPs by using the Pharmacists’  
Management of Drug-Related Problems (PMDRP)  
form 
- status of DRPs analysis of clinical results as  












To assess DPRs documented  
by specially trained  
community pharmacists  
during the Finnish  
comprehensive medication  
review (CMR) procedure and  
to describe the resulting  
interventions for home- 
dwelling and assisted-living  




living (n=51) primary 
care patients ≥65 
years. 
Pharmacists (n=26). 
- During the 1,5- 
year CMR  
accreditation  




- DRPs (PCNE classification for DRPs) 










To devise, implement and  
evaluate a medication  
adherence support service by  
community pharmacists for  
elderly patients living at home  
and at risk of non-adherence. 
Patients ≥65 years of 




- 8 (+/- 1) weeks Clinical:  
Indirect: 
- number of prescribed regular medicines 
- number and nature of medicine-related problems 
- self-reported adherence  
Humanistic: 
Economic:  
- cost of medication 
Twigg et al.  
2015 (24)  
Intervention  
To describe the effect of a  
holistic community  
pharmacy-based service with  
≥65 years of age, ≥4 
medicines (n=620) in 
25 community 
- 9/2012-6/2013 Clinical:  
Direct: 




patients over the age of 65  
years old and prescribed four  
or more medicines (FOMM) 
pharmacies of whom 
441 (71,1 %) 
completed the 6-
month study period. 
Indirect: 
- pharmacists’ recommendations 
- adherence (MMAS-8 score) 
Humanistic: 
- HRQoL (EQ-5D-5L) 
Economic:  
- the costs of intervention 
- cost per QALY  
ABDA = German Federation of Pharmacists 
ATC codes = Anatomical Therapeutic Chemical classification system 
CEAC = Cost-effectiveness acceptability curve 
DRP = Drug-related problem 
GP = General Practitioner  
HRQoL = Health-related quality of life 
MAI = Medication Appropriateness Index 
MMAS-8 = Morisky Measure of Adherence Scale-8 
PCNE = Pharmaceutical Care Network Europe 
PIM = Potentially Inappropriate Medications 
QALY = Quality-adjusted life year 
QoL = Quality of life 
RCT = Randomized controlled trial
Supplementary Table S3. Outcomes of the studies (n=16). 
Reference Community pharmacists’  
contribution to medication  
review intervention 
Outcomes of the studies 
Clinical outcomes Humanistic outcomes Economic outcomes 
I Prescription reviews 
RCTs (n=1) 
Denneboom et al. 2007 (13) • Identification of the patients 
to medication review 
intervention 
• Patient data collection 
• Conducting the medication 
review 
• Contacting the GP 
• Following up the patient (in 
a case-conference group) 
Indirect: 
- Pharmacists in the case- 
conference group identified  
significantly more  
recommendations themselves  
than the pharmacists in the  
written-feedback group (41,7 %  
vs. 34,2 %, p = 0.003) 
- 1569 recommendations were  
made (62% by the screening  
tool, 38% by the pharmacists) 
- more recommendations in  
case-conference group (p =  
0.059) 
- for clinically-relevant  
recommendations significantly  
more medication changes were  
initiated in the case-conference  
group (42 vs. 22, p = 0.02) 
- This was also seen for the  
percentage of maintained  
medication changes 6 months  
after the treatment reviews (36  
vs. 19, p = 0.02) 
  
Other studies (n=1)     
Denneboom et al. 2008 (14) 
Questionnaire, interviews 
• Identification of the patients 
to medication review 
intervention 
• Patient data collection 
• Conducting the medication 
review 
• Contacting the GP 
• Following up the patient (in 
a case-conference group) 
Indirect: 
- more recommendations to the  
GPs in case-conference group  
(chi-square, p = 0.059) 
- The number of  
recommendations with direct  
clinical relevance per patient is  
almost equal for both  
intervention groups 
- Health care professionals were  
more positive about the process  
of the treatment review  
presented personally although  
there were not always as many  
recommendations as they had  
hoped for 
- Both positive and negative  
factors influenced the results of  
-Pharmacists spent more time  
on the intervention than GPs  
did. 
- Health care professionals gave  
more of their time in the case  
conference-group than in the  
written feedback group 
- significantly more  
recommendations identified by  
the pharmacists themselves in  
case-conference group (chi- 
square, p = 0.003) 
- intervention with personal  
contact in case-conferences  
accepted better than an  
intervention with feedback in  
writing 
the intervention. Cooperation  
and personal relationship  
between the pharmacist and the  
GP were said to be both positive  
and negative in performing  
treatment reviews. The time  
required and specialists’  
prescriptions were named as  
negative factors influencing the  
results of the intervention. 
- concrete suggestions for  
improving the intervention such  
as a combination of case- 
conferences and written  
feedback and reserving the  
case-conferences for the most  
complex cases 
II Compliance and concordance reviews 
RCTs (n=3) 
Bernsten et al. 2001 (10) • Identification of the patients 
to medication review 
intervention  
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
Indirect: 
- The medical conditions were  
controlled better during the  
study in intervention group (at 6  
months 73 %, at 12 months 71  
% and at 18 months 75 % of the  
patients agreed) 
- No significant differences  
between the control and  
intervention with regard to  
prescription and nonprescription  
drug use. 
- 50 % of GPs considered the  
recommendations 
- there were significantly more  
changes in medication self- 
reported by the intervention  
group than by the control group  
at baseline and the 6-month  
assessment (Mann-Whitney  
test, p < 0.05) 
- No significant differences  
-HRQoL declined in both  
groups in general except in  
some domains in some  
countries: significant  
improvements in general health  
and role emotional scores  
compared to control patients in  
Denmark (independent t-test, p  
< 0.05)  
- In the pooled 
data, there were no significant  
differences between 
the control and intervention  
patients in any of the 
8 dimensions over time (AUC  
summary measure analysed;  
independent t-test, p > 0.05)  
- patients in intervention and  
control groups were satisfied  
with the services but  
intervention patients rated the  
services significantly higher at 6  
-No significant differences  
between the total cost for  
control and intervention patients  
in any country (Mann-Whitney,  
p > 0.05) 
- Some significant differences  
in individual components (e.g.  
in Germany intervention  
patients had significantly lower  
costs associated with  
hospitalisations and contact  
with specialists compared to  
controls (Mann-Whitney test, p  
< 0.05) 
- more hospital visits in control  
group (non-significant) 
- No significant differences  
between the control and  
intervention regard to contact  
with GPs 
between the control and  
intervention with regard to  
knowledge of medicines  
- at 18 months significantly  
higher proportion of the  
intervention patients changed  
from being noncompliant to  
compliant compared with the  
control patients (15,2 %  and  
12,2 , respectively; Chi-squared,  
p = 0.028)  
and 18 months compared to  
control patients (Mann-Whitney  
test, p < 0.05 ) and there were  
statistically significant increases  
in satisfaction in the  
intervention group over time  
(baseline 92,0 % vs. 6 months  
95,1 %, Wilcoxon test, p =  
0.012; baseline 92,0 % vs. 12  
months 93,9 %, Wilcoxon test,  
p = 0.039) 
- 80 % of pharmacists and 52 %  
of GPs had a positive opinion of  
pharmaceutical care 
Sturgess et al. 2003 (12) • Identification of the patients 
to medication review 
intervention 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
Indirect: 
- The medical conditions were  
controlled better during the  
study in intervention group  
(proportion of patients who  
agreed: 6 months 87,8 %, 12  
months 85,1 %, 18 months 83,1  
%) 
- fewer problems with their  
medicines in intervention group  
compared to control during the  
last 6 months of the study  
(Mann-Whitney, p < 0.05) 
- No significant differences in  
medicines use between  
intervention and control group 
- 60,8 % (n=124) of the patients  
problems (n=204) identified led  
to positive outcomes 
- compliance with medication  
significantly higher in  
intervention patients compared  
to control patients (chi-square, p  
< 0.05) 
- patient knowledge of  
medicines were comparable in  
intervention and control groups 
--HRQoL declined in  
intervention group and  
improved in control group in  
some of the SF-36 dimensions  
(physical functioning and  
vitality, independent t-test, p <  
0.05) 
- All patients rated services  
excellent or good 
- GPs had positive opinion  
about service 
- Pharmacists had a positive  
opinion on the pharmaceutical  
care programme 
-total costs 131,65£ lower per  
patients in intervention group  
than in control group during the  
intervention (Wilcoxon test, p >  
0.05) 
- Intervention patients incurred  
lower costs associated with their  
prescribed medicines compared  
to control patients (Mann- 
Whitney test, p > 0.05) 
- fewer intervention patients  
were hospitalized (non- 
significant) 
- little impact of health care  
utilizations 
Casteel et al. 2011 (20) • Identification of the patients 
to medication review 
intervention 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
Indirect: 
-14 of 31 prescribers responded  
(45,2 %) 
-10 prescribers authorized all  
the changes 
-10 of 41 recommendations  
were implemented by the  
patient (24,4 %) 
-73 medication reviews were  
completed: 
-41 recommendations were  
made to 32 patients 
  
Other studies (n=4) 
Fiß et al. 2013 (23) 
A prospective non-randomized  
implementation cohort study 
• Patient data collection 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
Indirect: 
- self-reported ADRs decreased  
non-significantly (McNemar, p  
= 0.564) 
- The proportion of patients  
taking PIM according to the  
Beers’ criteria was reduced non- 
significantly (p = 0.07) 
- number of active substances  
taken was reduced from 8 to 7 
- the proportions of patients  
using medication charts and  
compliance aids increased  
significantly (p < 0.001) 
- self-reported forgetfulness (p  
= 0.001), proportion of  
intermittent drug intake (p <  
0.001) and the proportion of  
patients with potentially clinical  
relevant drug-drug interactions  
(p < 0.001) reduced  
  
Kassam et al. 2001 (11) 
A process description 
• Identification of the patients 
to medication review 
intervention  
• Patient data collection 
• Interviewing the patient 
Indirect: 
- 559 DRPs were found in 145  
patients; 39% actual and 60 %  
potential, 1% not labelled 
- average 3,9 DRPs per patient  
- The most frequent DRP  
categories were where patient  
  
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
requires drug therapy or  
requires influenza or  
pneumococcal vaccination 
- pharmacists made 613  
recommendations; 502 to  
patients (mostly recommending  
pneumococcal or influenza  
vaccines) and 247 to physicians 
- physicians accepted 72 % and  
patients 76 % of  
recommendations 
- 551 SOAP (subjective,  
objective, assessment, plan)  
notes were written and 346  
follow-up interventions  
recorded (62% of identified  
DRPs) 
- in 80% of the situations  
pharmacist consulted directly  
patient 
- in follow-up 40 % of the  
DPRs were resolved, controlled  
or improved. 
Raynor et al. 2000 (9)  
Intervention study 
• Identification of the patients 
to medication review 
intervention  
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
Indirect: 
- 441 DRPs were identified of  
which 55 % (n=241) required  
the provision of information or  
advice, 24 % (n=106) required  
consultation with the GP and  
20% (n=80) required changes in  
the presentation of the  
medicines 
- the number of patients with  
one or more problems reduced  
from 94 % to 58 % (McNemar,  
p < 0.001) 
-the median number of regular  
prescribed medicines fell from 6  
to 5 (Wilcoxon ranked pairs, p  
< 0.001) 
- the proportion of patients who  
 -the average cost per patient of  
oral prescription medication for  
28 days fell from £51,12 to  
£44,55 (Wilcoxon, p < 0.001) 
- the support program resulted  
in projected savings of £52 per  
patient per year  
reported non-adherence fell  
from 38 % to 14 % (McNemar,  
p < 0.001) 
Twigg et al. 2015 (24)  
Intervention study 
• Identification of the patients 
to medication review 
intervention  
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
Direct: 
- a significant reduction (mean  
0.116 (95% CI, -0.217 to - 
0.014)) in the total number of  
falls 
- pain scores over the course of  
the evaluation period appeared  
to increase (non-significantly) 
 
Indirect: 
- pharmacists made 142  
recommendations to prescribers  
centered on potentially  
inappropriate prescribing of  
NSAIDs, PPIs or duplication of  
therapy 
- adherence to medication  
improved significantly (0.513  
(95% CI, 0.337 to 0.689)  
difference in scores) 
-Quality of life improved  
significantly (mean change in  
score of 0.025 (95% CI, 0.007  
to 0.042) 
- cost of the intervention was  
estimated to be £98.72 per  
participant 
- cost per quality-adjusted life  
year estimates ranged from  
£11 885 to £32 466 depending  
on the assumptions made 
- based on the CEAC, at £20  
000 per QALY, the probability  
of being cost-effective was  
13.8% 
III Clinical medication reviews 
RCTs (n=1) 
Bryant et al. 2011 (19) • Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
Indirect: 
- MAI significantly improved in  
the intervention group (at 6  
months: 2.0 points; 95%  
confidence interval 1.32 to 2.68,  
p < 0.001) 
- 2,8 recommendations per  
patient in the intervention group 
- in the first 6 months, 38% of  
the pharmacists’  
recommendations were  
implemented and 12% partially  
implemented and in 12 months  
46 % were implemented and 16  
% partially implemented 
- 3,1 changes (intervention) vs.  
- QoL: emotional role (13.4 unit  
difference, p = 0.024 and social  
functioning (7.7 unit difference,  
p = 0.019) significantly reduced  
in intervention group compared  
with the control 
 
1,8 changes (control) per patient  
in the first 6 months 
- significantly more medicines  
started in the control group (p <  
0.0001) 
- significantly more dosage  
reductions and medicines  
switches in the intervention  
group (p = 0.037) 
Other studies (n=6) 
Bryant et al. 2010a (15)  
Interview 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
 -Community pharmacists  
perceived that they were not  
mandated to undertake this role  
and it was not a legitimate role.  
They were concerned that they  
lacked the skills and confidence  
to provide this level of input. 
 
Bryant et al. 2010b (16)  
Interview 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Counselling the patient 
• Contacting the GP 
• Following up the patient 
 -Two themes: patient outcomes  
(clinical vs. theoretical  
recommendations) and resource  
utilisation (time and funding)  
were balanced which  
determined the value. This led  
to a continuum between positive  
and negative responses. 
 
Castelino et al. 2010a (17) 
A retrospective analysis 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Contacting the GP 
Indirect: 
- the median cumulative patient  
MAI scores were significantly  
lower after the HMR (18.6 +/-  
11.3 vs. 9.3 +/- 7.5), as  
interpreted from the pharmacist  
recommendations (p < 0.001) 
  
Castelino et al. 2010b (18) 
A retrospective analysis 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
• Contacting the GP 
Indirect: 
- significant reduction in the  
sum of total of DBI scores for  
all patients was observed  
following pharmacist  
recommendations during the  
HMR service (206.9 vs. 157,3,  
Wilcoxon signed-rank test, p <  
  
0.001) 
- of the 372 patients, 148 (39,8  
%) were prescribed one or more  
PIMs 
- pharmacists’  
recommendations led to a  
decrease in the use of PIMs,  
which were identified in 105  
(29,2 %) patients of the 372  
patients 
- ceasing the sedative or  
anticholinergic medication was  
the most frequently  
recommended action 
- pharmacists’  
recommendations during the  
HMR service, medications  
contributing to the DBI were  
identified in 51.6% (n = 192) of  
the patients.  
Freeman et al. 2012 (21) 
A retrospective analysis of  
medication reviews with two  
time periods 
• Patient data collection   - 56% of the medication  
reviews from pre-integration  
phase and 6% from the post- 
integration phase were not  
billed which demonstrates a  
potential financial saving of  
AUS$ 17 374 during the post- 
integration phase 
- the time to complete the  
medication review process was  
significantly reduced from  
median of 56 days to 20 (p >  
0.001) 
- in the post-integration phase  
more patients were seen within  
2 and 4 weeks when compared  
to the pre-integration phase 
Leikola et al. 2012 (22) 
A retrospective analysis 
• Patient data collection 
• Interviewing the patient 
• Conducting the medication 
review 
Indirect: 
- community pharmacists  
reported 785 potential DRPs  
(average of 6.5 per/patient)  
  
• Contacting the GP - the mean number of DRPs was  
higher for home-dwelling  
patients (7.2) than for the  
patients living in assisted-living  
setting (5.5) (p = 0.014) but  
similar in nature 
- The most common DRPs were  
inappropriate drug selection (17  
% of DRPs) involving most  
often hypnotics and sedatives.  
Also, indications with no  
treatment were common (16%),  
particularly those associated  
with cardiovascular diseases  
and osteoporosis, the  
distribution of DRPs was  
similar in both groups 
- in 51% of DRPs (n=403),  
CMRs resulted in change of  
drug therapy; stopping a drug  
was the most common change 
- pharmacists made 649  
recommendations, of which  
55% (n=360) were accepted by  
physicians without revision 
ADR = Adverse drug reaction 
CEAC = Cost-effectiveness acceptability curve 
CMR = Comprehensive medication review 
DBI = Drug Burden Index 
DRP = Drug-related problem 
GP = General practitioner  
HMR = Home Medicines Review 
HRQoL = Health-related quality of life 
MAI = Medication Appropriateness Index 
NSAID = Nonsteroidal anti-inflammatory drug 
PIM = Potentially Inappropriate Medications 
PPI = Proton pump inhibitor 
QALY = Quality-adjusted life year 
QoL = Quality of life 
RCT = Randomized controlled trial 
SOAP = Subjective, objective, assessment, plan
 
 
